Nerelimomab

Drug Profile

Nerelimomab

Alternative Names: BAY 1351; BAY X 1351; Norasept

Latest Information Update: 02 Jul 1997

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chiron Corporation
  • Developer Celltech Group; Chiron Corporation
  • Class Anti-TNF monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Septic shock

Most Recent Events

  • 02 Jul 1997 Discontinued-I for Septic shock in Japan (IV)
  • 02 Jul 1997 Discontinued-III for Septic shock in France (IV)
  • 02 Jul 1997 Discontinued-III for Septic shock in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top